KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Vertex Pharmaceuticals (VRTX) Equity Average (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 16 years of Equity Average data on record, last reported at $18.0 billion in Q4 2025.

  • For Q4 2025, Equity Average rose 12.31% year-over-year to $18.0 billion; the TTM value through Dec 2025 reached $18.0 billion, up 12.31%, while the annual FY2025 figure was $17.5 billion, 3.19% up from the prior year.
  • Equity Average reached $18.0 billion in Q4 2025 per VRTX's latest filing, up from $17.2 billion in the prior quarter.
  • Across five years, Equity Average topped out at $18.1 billion in Q1 2024 and bottomed at $8.8 billion in Q1 2021.
  • Average Equity Average over 5 years is $14.1 billion, with a median of $15.1 billion recorded in 2023.
  • Peak YoY movement for Equity Average: soared 40.81% in 2021, then dropped 8.92% in 2025.
  • A 5-year view of Equity Average shows it stood at $9.8 billion in 2021, then surged by 37.25% to $13.5 billion in 2022, then grew by 26.54% to $17.0 billion in 2023, then fell by 6.02% to $16.0 billion in 2024, then grew by 12.31% to $18.0 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Average were $18.0 billion in Q4 2025, $17.2 billion in Q3 2025, and $16.8 billion in Q2 2025.